-
Canada needs a national system for cancer clinical trials
Toronto Star – Clinical trials are the most effective means of ensuring we have better cancer treatments. Such an investment would help overcome many hurdles facing clinical trials – from underfunding and suboptimal testing capacity to inefficient and costly regulatory processes. By Janet Dancey Contributor “A bad system will beat a good person every time.” William Edwards Deming…
-
impACCT Virtual Rounds Winter Session 2024
When: Thursday, March 7, 2024 12:00 pm -1:15 pm ESTTrial #1: OCOG-2022-ROSALIE: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy https://clinicaltrials.gov/study/NCT05866458 Speaker: Dr. Elena Parvez, MD, Assistant Professor, Department of Surgery, McMaster University; Surgical Oncologist at the Juravinski Hospital and Cancer Centre…
-
2022-23 3CTN Impact Report
Check out the accomplishments of Network Sites and the 3CTN Coordinating Centre.
-
-
impACCT Virtual Rounds Fall Session 2023
When: Thursday, Sept 28, 2023, 12:00 pm -1:00 pm EDT Trial #1: (UHN) PLAN Prevention of persistent pain with Lidocaine infusions in breast cancer surgery Speaker: James Khan, MD, Assistant Professor and Clinician-Scientist, Department of Anesthesia and Pain Medicine, University of Toronto. Trial #2: (CCTG) CRC.10 / NRG-GI008 A phase II/III study to determine chemotherapy recommendations…
-
-
Network Pulse June 2023
Read about activities happening at 3CTN member sites and get important updates about 3CTN goals and achievements.
-
3CTN’s Annual Stakeholder Meeting (ASM) & Workshops 2023
3CTN is excited to announce that our upcoming Annual Stakeholder Meeting (ASM) & Workshops will be held on October 26-27 2023 in Toronto, please save the date! Registration is now open. Agenda and further details to follow.
-
-
impACCT Virtual Rounds Spring Session 2023
The Canadian Cancer Clinical Trials Network (3CTN) is pleased to announce the next impACCT Virtual Rounds Spring Session. When: Tuesday, May 16, 2023 12:00 pm -1:00 pm EDT Trial #1: (UoA) ACIT001 / EXC002 A phase 1b/2 multi-center, de-centralized, dose selection study of autologous CD19-directed chimeric antigen receptor (CAR) T-cells in patients with relapsed/refractory aggressive lymphoma…
News and Events
Categories
- EDGE Essentials (2)
- Event (16)
- Network Pulse (4)
- News (14)
- Portfolio Watch (13)